Achieve life sciences announces patent granted by uspto for new cytisinicline formulation

Seattle, wash and vancouver, british columbia, dec. 21, 2022 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the united states patent and trademark office (uspto) has issued u.s. patent no. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development.
ACHV Ratings Summary
ACHV Quant Ranking